Orrick, Herrington & Sutcliffe LLP’s Post

🧩 With new patent guidelines in place, you might be wondering what role AI can play in drug discovery🔬 It’s an issue Fenwick partners Antonia Sequeira, Hayan Yoon, and associates Pinar Erciyas Bailey, Malashaan Kind, and Fredrick Tsang are diving into head-first. Attend their upcoming webinar to learn: ⚡What is—and isn’t—covered under new U.S. patent guidelines ⚡Strategies and potential pitfalls in AI-assisted drug discovery ⚡Precautions to maximize patent coverage Register here: https://bit.ly/4a4F2qS How have you approached your AI-assisted drug discovery? #LifeSciences #ArtificialIntelligence #Patents

We are delivering this FREE webinar in partnership with Global IP Strategy Hub. Will Arends will be moderating the discussion on the Biopharma Patent Ecosphere: Global Updates on G2/21, Plausibility, Efficiency and Enablement. 📅 Tuesday 24 September 🕛 09.00 EST | 15.00 CET | 60 minutes Check out the details below for full details of key discussion points and how to register. 👇 #IP #global #intellectualproperty

Free Webinar: Navigating the Psychedelic Patent Landscape - Inclusive Strategies for Innovation and Protection Dates: June 17, 2024 Time: 11:00 am Eastern Time Join Porta Sophia | Psychedelic Prior Art Library for a comprehensive webinar as they examine the patent landscape around psychedelic inventions and intellectual property. This webinar will provide a detailed overview of the technological landscape, patentability requirements, and unique challenges in the field. They are excited to feature a panel of diverse experts and stakeholders, including consideration of Indigenous perspectives in patenting psychedelic medicine, rooted in millennia of Indigenous history.   The webinar will also provide insights from stakeholders in key areas of the psychedelic patent ecosystem including investments, legal practices, and emerging therapies. Porta Sophia and expert panelists will guide participants on drafting claims that respect the public domain, navigating patent challenges, and implementing risk mitigation strategies for effective IP acquisition. REGISTER: https://lnkd.in/gj-Yg82U   This webinar, ideal for researchers, legal professionals, investors, and entrepreneurs in the psychedelic field, offers tools and insights for innovating and protecting intellectual property. Open to the public and free to register, we invite the psychedelic community to join us and learn about inclusive and effective strategies in this evolving space. ORGANIZED AND PRODUCED BY Arrowhead Sci-Tech Conferences & Events (the producers of the Annual Psychedelic Therapeutics & Drug Development Conference) https://lnkd.in/eM5iiPn Sisi Li, Ph.D. Juliet M. Simeon Schnapper Jeremy Rolquin María Islas Graham Pechenik Kimberly Chew #psychedelics #psychedelicresearch

The latest issue of Mathys Matters is out! This month's spotlight is on the Mathys & Squire teams being recommended in The Legal 500 2025 directory for their “unparalleled knowledge and experience in all areas of intellectual property” This issue also includes articles on #CRISPR patents being pulled from EPO appeals citing procedural concerns, the #EPO Board of Appeal finding no basis in the EPC for requiring description amendments, and opts not to refer questions to the Enlarged Board, emerging therapeutics and technology provide hope for menopause management, and semiconductor patent applications growing 22% globally to 81,000 a year. Click here to read more: https://bit.ly/4htI1y4

OPEN ACCESS : Drug Hunter Annotated Patent Database Search | https://lnkd.in/gVcHfBND As part of our series of monthly patent roundup articles, which bring you the most relevant drug discovery IP disclosures, we have collated our annotated database into a single searchable table. This tool, which is Open Access while in development, allows you to see longer term-industry trends in therapeutic area and target selection to give your drug discovery project the competitive edge you've been looking for. Try it out during our free, open access period to get a taste of the insights that Drug Hunter members are able to use to solve their drug discovery challenges | https://lnkd.in/gVcHfBND

Thrilled to kick off our 2024 .PermeabilitySeries tomorrow: "Practical Applications of In-Vitro Permeability in Formulation Development" I'm honored to host Travis Webb from CoreRx, Inc., as our keynote speaker. Travis will unravel the complexities of permeability testing, highlighting its pivotal role in #formulation development and its broader implications in the pharmaceutical landscape. Why Focus on #InVitro Permeability? In the meticulous process of drug development, understanding in-vitro permeability is crucial. It offers a glimpse into the future, predicting pharmacokinetic outcomes such as Tmax, Cmax, AUC, and fraction absorbed, which are fundamental in shaping effective and innovative drug formulations. This webinar is about leveraging in-vitro insights to foresee in-vivo pharmacokinetics, fostering breakthroughs in how we approach drug formulation and delivery. 📅 Date: March 6th, 2024 ⏰ Time: 3 PM CET >>> register for free: https://lnkd.in/eXHPt8U6 #PermeabilitySeries #PharmaInnovation #DrugDevelopment #Webinar

Last week USPTO released new guidelines for assessing enablement following the Supreme Court's decision in Amgen v. Sanofi affirming use of the traditional Wands factors to evaluate enablement. The guidelines also discuss several Federal Circuit Court cases following Amgen v. Sanofi that found genus claims invalid for lack of enablement throwing more cold water on patent applicants in Life Sciences, which is considered an "unpredictable" art under the Wands factors. As a reminder, the Wands factors include: (A) The breadth of the claims; (B) The nature of the invention; (C) The state of the prior art; (D) The level of one of ordinary skill; (E) The level of predictability in the art; (F) The amount of direction provided by the inventor; (G) The existence of working examples; and (H) The quantity of experimentation needed to make and use the invention based on the content of the disclosure. (MPEP 2164.01(a).) Read more on the MoFo Life Science Blog. https://lnkd.in/gc_Z8J8f

How often has attorney Mandy Decker from Stites & Harbison, PLLC, been recognized on Managing IP's "Top 250 Women in IP" list? This year marks her 10th appearance! Known for her prowess in intellectual property law and patent prosecution, Decker's scientific background in chemistry and experience with academic and commercial research in the areas of biochemistry, biotechnology, and pharmaceutical sciences further distinguishes her as one of the top figures in the field. Congratulations! Click the link below to learn more: https://lnkd.in/eehWRWnZ #IPlaw #IPstars #IntellectualProperty

𝐓𝐨 𝐛𝐞 𝐚 𝐟𝐨𝐫𝐜𝐞 𝐟𝐨𝐫 𝐠𝐨𝐨𝐝 𝐢𝐧 𝐭𝐡𝐞 𝐰𝐨𝐫𝐥𝐝. ▶ In 2007, Verdis Norton and atomic medical physicist Dr. Gary Samuelson faced a crossroads. ▶ Across the table sat representatives from a giant pharmaceutical company who had flown in from New Jersey to evaluate Verdis' proprietary redox  technology. ▶ These representatives anxiously awaited a response to their multi-million dollar offer for his patents and research. ▶ Verdis was left with a heavy decision. ▶ Should he choose the money or prioritize the people benefiting from this incredible redox solution? ▶ If he sold, would the world get access to this groundbreaking solution that had the potential to change the face of health and medicine? ▶ In a decision rooted in integrity and compassion, Verdis chose the people. ▶ At 67, he came out of retirement and launched ASEA with a mission and vision to better lives globally through leading redox technologies. _ _ _ 👆 Join me in this journey. Discover how ASEA's redox technologies can make a difference in your life and practice. Explore -> www.liveyoungerlonger.com Experiences like Jimmy Ferguson in the video exemplify the impact of Verdis's decision. 𝐁𝐞𝐜𝐚𝐮𝐬𝐞 𝐬𝐨𝐦𝐞𝐭𝐢𝐦𝐞𝐬, 𝐜𝐡𝐨𝐨𝐬𝐢𝐧𝐠 𝐩𝐞𝐨𝐩𝐥𝐞 𝐨𝐯𝐞𝐫 𝐩𝐫𝐨𝐟𝐢𝐭 𝐜𝐚𝐧 𝐜𝐡𝐚𝐧𝐠𝐞 𝐭𝐡𝐞 𝐰𝐨𝐫𝐥𝐝.

It's not too late to join Will Arends and the rest of the panel later today as they discuss the Biopharma Patent Ecosphere: Global updates on G2/21, Plausibility, Sufficiency and Enablement. Interested? Registration is completely FREE. Click here 👉 https://lnkd.in/esB_3Sze We look forward to seeing you online later today. #IP #IntellectualProperty